文献速递浆细胞疾病

多发性骨髓瘤美国FDA药物批准试验中的种族和民族差异分析

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.
PubMed 文献 · Blood Adv · 2022-01-01

该汇总分析纳入2006至2019年支持美国FDA批准多发性骨髓瘤治疗药物的19项全球试验共10157例患者,描述性分析人口学特征并用年龄校正分层Cox回归评估结局与种族的关系。黑人和西班牙裔患者在试验中代表性不足,黑人患者主要在美国入组,美国患者结局优于世界其他地区患者,作者认为应改善非裔美国人在多发性骨髓瘤临床试验中的代表性。

要点

  • 数据集白人占84%、亚裔占7%、黑人占4%、西班牙裔占4%。
  • 黑人 vs 白人年龄校正总生存HR为0.89(95%CI 0.75-1.05)。
  • 美国黑人 vs 美国白人年龄校正HR为0.82(95%CI 0.66-1.02),世界其他地区黑人 vs 白人HR为1.31(95%CI 0.97-1.77)。

核心结论

  • 黑人和西班牙裔患者在支持FDA批准多发性骨髓瘤药物的试验中代表性不足。
  • 黑人患者主要在美国入组,美国患者结局优于世界其他地区患者。
  • 鉴于非裔美国人多发性骨髓瘤发病率更高且疾病特征不同,作者认为应努力改善非裔美国人在多发性骨髓瘤临床试验中的代表性。

研究设计与样本

  • 对2006至2019年提交美国FDA以支持多发性骨髓瘤治疗药物批准的所有试验进行汇总分析。
  • 共纳入19项全球试验、10157例患者。
  • 人口学特征采用描述性分析,采用年龄校正分层Cox回归模型评估至事件结局与种族和民族的关系。

主要发现

  • 数据集中白人、亚裔、黑人患者分别占84%、7%、4%;西班牙裔患者占4%。
  • 黑人 vs 白人年龄校正总生存HR为0.89(95%CI 0.75-1.05)。
  • 美国黑人 vs 美国白人年龄校正HR为0.82(95%CI 0.66-1.02)。
  • 世界其他地区黑人 vs 世界其他地区白人HR为1.31(95%CI 0.97-1.77)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

African Americans (AAs) have a higher incidence of multiple myeloma (MM) than White patients. Mortality is also higher in AAs compared with White patients. AAs more commonly have immunoglobulin H translocations t(11;14) and t(14;16) compared with White patients. We sought to characterize the demographic representation in MM clinical trials and evaluate outcomes based on race and ethnicity. We conducted a pooled analysis of all trials submitted to the US Food and Drug Administration (FDA) to support approval of a MM therapeutic between 2006 and 2019. Demographic characteristics were analyzed descriptively. An age-adjusted stratified Cox regression model was used to evaluate the relationship between time-to-event outcomes and race and ethnicity. Nineteen global trials comprising 10 157 patients were pooled. White, Asian, and Black patients comprised 84%, 7%, and 4% of the dataset, respectively; Hispanic patients comprised 4%. The age-adjusted overall survival hazard ratio (HR) for Black compared with White patients was 0.89 (95% confidence interval [CI], 0.75-1.05). The age-adjusted HR for US Black vs US White patients was 0.82 (95% CI, 0.66-1.02). For rest-of-world (RoW) Black vs RoW White patients, the HR was 1.31 (95% CI, 0.97-1.77). Black and Hispanic patients were underrepresented in the trials supporting FDA approval of MM drugs. Black patients were primarily enrolled in the United States. Outcomes in US patients were more favorable compared with those in patients in the RoW. Given the higher incidence of MM in AAs and the different disease characteristics, efforts should be made to improve representation of AAs in MM clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kanapuru B, Fernandes LL, Fashoyin-Aje LA, et al. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Adv. 2022. PMID: 35114691. doi:10.1182/bloodadvances.2021005482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。